

# Mark C. Granberry

## Curriculum Vitae

---

Office Address  
4301 West Markham St  
Little Rock, Arkansas  
Telephone: 501-526-5581  
e-mail:mgranberry@uams.edu

Home Address  
123 Linwood Ct.  
Little Rock, Arkansas 72205  
210-255-0870

### EDUCATION

---

Clinical Residency in Cardiovascular Pharmacotherapy  
University of Arkansas College of Pharmacy  
Little Rock, Arkansas  
July 1994 - June 1995

Pharmacy Practice Residency  
University Hospital of Arkansas  
Little Rock, Arkansas  
July 1993 - June 1994

Doctor of Pharmacy  
University of Arkansas College of Pharmacy  
Little Rock, Arkansas  
August 1994

Bachelor of Science in Pharmacy  
University of Arkansas College of Pharmacy  
Little Rock, Arkansas  
June 1978

### LICENSURE

---

Arkansas, State Board of Pharmacy # 6457  
Texas, State Board of Pharmacy # 41497

### PROFESSIONAL EXPERIENCE

---

Professor and Vice Chair of Pharmacy Practice  
UAMS College of Pharmacy  
4301 West Markham St.  
Little Rock, Arkansas 72205  
July 2017 to present

Professor and Vice Chair of Pharmacy Practice  
Irma Lerma Rangel College of Pharmacy  
Texas A&M Health Science Center  
1010 West Avenue B, MSC 131  
Kingsville, Texas 78363  
May 2011 to June 2017

Professor with Tenure  
Feik School of Pharmacy  
The University of the Incarnate Word  
4301 Broadway, CPO 99  
San Antonio, Texas 78209

January 2009 to December 2010

Associate Professor, Tenure awarded 2007  
Assistant Dean and Chair, Pharmacy Practice  
Feik School of Pharmacy  
The University of the Incarnate Word  
4301 Broadway, CPO 99  
San Antonio, Texas 78209  
February 2005 to December 2008

Associate Professor with Tenure September 2004 to December 2004  
Cooperative Pharmacy Program  
The University of Texas – Pan American  
1201 West University Drive, HSW 1.130  
Edinburg, Texas 78541  
Assistant Professor October 2002 to August 2004

Associate Professor with Tenure, Department of Pharmacy Practice  
College of Pharmacy – July 2001 to September 2002  
University of Arkansas for Medical Sciences  
4301 West Markham St., Slot 522  
Little Rock, Arkansas 72205  
July 2001 to September 30, 2002  
Assistant Professor - July 1995 to June 2001

Responsibilities include instruction of the Cardiology module of the Therapeutics course, coordinator of Pharmacy Practice - Advanced Cardiovascular Therapeutics, coordinator of ambulatory care Lipid Clinic, as well as selected lectures in other courses, precepting students, patient care rounds with the Cardiology teams, conducting clinical research and service through committee work.

Staff Pharmacist  
Baptist Memorial Medical Center  
One Pershing Circle  
North Little Rock, Arkansas 72114  
July 1978 to June 1993

Responsibilities included IV admixture, chemotherapy, TPN, computerized unit dose, pharmacokinetics consults, drug utilization evaluation (DUE), "Code Blue" team member, inservice to pharmacy and nursing staff, preceptor for University of Arkansas College of Pharmacy, member of the advisory committee for the Recuperative Care Unit.

Westside Free Medical Clinic  
2415 North Tyler Street  
Little Rock, Arkansas 72207  
December 1989 - 2000

Review charts and fill prescriptions in a clinic setting, provide information to patients and professional staff.

Oscop Drug, Inc.  
3929 McCain Boulevard  
North Little Rock, Arkansas 72116  
September 1977 - June 1978

Responsibilities included patient counseling, filling prescriptions, maintaining patient profiles, drug procurement.

## PROFESSIONAL MEMBERSHIPS

---

American Association of Colleges of Pharmacy  
American College of Clinical Pharmacy  
Texas Society of Health-System Pharmacists

## CERTIFICATION

---

Advanced Cardiac Life Support (ACLS)  
April 1995 - Present

Basic Life Support (BLS)  
July 1993 – Present

## INSTRUCTION

---

**Lecturer**, Pharmacology II. A required course for Pharm.D. candidates in their second professional year. University of Arkansas for Medical Sciences College of Pharmacy, 2018 to present

**Lecturer**, Therapeutics II. A required course for Pharm.D. candidates in their second professional year. University of Arkansas for Medical Sciences College of Pharmacy, 2018 to present

**Lecturer and Course Coordinator**, Landmark Studies. An elective course for Pharm.D. candidates in their third professional year. University of Arkansas for Medical Sciences College of Pharmacy, 2017 to present

**Lecturer and Co-Course Coordinator**, PHAR 778, Drug Literature Evaluation and Patient Education. A required course for Pharm.D. candidates in their second professional year. Texas A&M Health Science Center Rangel College of Pharmacy, 2013 to 2015

**Faculty Advisor**, Independent Study, PHAR 785. An elective course advising students on an independent study project. Texas A&M Health Science Center Rangel College of Pharmacy

Purvi Patel	Fall 2012
Kristen Gillland	Spring 2013

**Preceptor**, Advanced Pharmacy Practice Experience, a cardiology elective clerkship for Pharm.D. candidates in their fourth professional year. Texas A&M Health Science Center Rangel College of Pharmacy, 2012 to 2017

**Lecturer and Co-Course Coordinator**, Integrated Pharmacotherapeutics II: Cardiovascular (PHAR 711). A required course for Pharm.D. candidates in their second professional year. Texas A&M Health Science Center Rangel College of Pharmacy, 2011 to 2016

**Lecturer and Course Coordinator**, Landmark Studies. An elective course for Pharm.D. candidates in their third professional year. Texas A&M Health Science Center Rangel College of Pharmacy, 2011 to 2017

**Lecturer and Course Coordinator**, Pharmacotherapeutics IX: Musculoskeletal Diseases. (PHAR 52463) a required course for Pharm.D. candidates in their third professional year. University of the Incarnate Word School of Pharmacy, 2008

**Lecturer and Course Coordinator**, Landmark Studies (PHAR5276) an elective course for Pharm.D. candidates in their third professional year. University of the Incarnate Word School of Pharmacy, 2008 - 2010

**Lecturer and Course Coordinator**, Pharmacotherapeutics V: Cardiovascular Diseases. (PHAR 4543) a required course for Pharm.D. candidates in their second professional year. University of the Incarnate Word School of Pharmacy, 2008 - 2010

**Lecturer and Course Coordinator**, Drug Information. (PHAR3157) a required course for Pharm.D. candidates in their first professional year. University of the Incarnate Word School of Pharmacy, 2007 - 2008

**Lecturer and Course Coordinator**, Pharmacotherapeutics for Clinical Nurse Specialists, 2006 - 2010

**Lecturer**, Integrated Health Science (NURS2310) a required course for first year baccalaureate nursing students. University of the Incarnate Word School of Nursing, 2007-2008.

**Lecturer and Course Coordinator**, Professional (Applied) Development Skills. (PHAR 1105), a required course for pre-pharmacy candidates in their second year, University of the Incarnate Word School of Pharmacy, 2005 – 2008

**Lecturer**, Applied Pharmacy Care III (PHAR4230) a required course for Pharm.D. candidates in their second professional year. University of the Incarnate Word School of Pharmacy, 2007 – 2008

**Lecturer**, Ethics and Life Issues (PHAR3150) a required course for Pharm.D. candidates in their first professional year. University of the Incarnate Word School of Pharmacy, 2006 - 2010

**Lecturer and Course Coordinator**, Landmark Studies in Cardiovascular Pharmacotherapy. (Phr277k), an elective course of Pharm.D. candidates in their third professional year, University of Texas at Austin College of Pharmacy, 2004

**Preceptor**, Adult Medicine Clerkship, a cardiology elective clerkship for Pharm.D. candidates in their fourth professional year. Cooperative Pharmacy Program, University of Texas – Pan American and University of Texas at Austin College of Pharmacy, 2003 - 2005

**Lecturer and Course Coordinator**, Medical Terminology, (HRP2303), College of Health Sciences and Human Services, University of Texas – Pan American, 2003 - 2005

**Lecturer and Course Coordinator**, Human Physiology, (OTTC3301), Occupational Therapy Program, University of Texas – Pan American, 2003

**Preceptor**, Academic Clerkship, an elective clerkship for Pharm.D. candidates in their fourth professional year. Cooperative Pharmacy Program, University of Texas – Pan American and University of Texas at Austin College of Pharmacy, 2003 - 2005

**Lecturer**, Pharmacology I and Pharmacology II, (PHAS3228 and PHAS3329) Physician Assistant Studies Program, University of Texas – Pan American 2002 to 2005

**Lecturer and Course Coordinator**, Advanced Cardiovascular Pharmacotherapy: Case-Based Studies (PhPr5632), an elective course of Pharm.D. candidates in their third professional year, University of Arkansas College of Pharmacy 2001 - 2002.

**Lecturer**, Introduction to Patient Monitoring. (PhPr4224), a required course for Pharm.D. candidates in their second professional year, University of Arkansas College of Pharmacy 2000 – 2002.

**Lecturer**, Contemporary Issues in Pharmacy Practice. (PhPr5692), an elective for Pharm.D. candidates in their second professional year, University of Arkansas College of Pharmacy 1999-2000.

**Lecturer**, Landmark Studies and Consensus Statements. (PhPr5892), an elective for Pharm.D. candidates in their third professional year, University of Arkansas College of Pharmacy 1998 – 2002.

**Lecturer and Laboratory Instructor**, Physical Assessment. (PhPr5634), a required course for Pharm.D. candidates in their third professional year, University of Arkansas College of Pharmacy 1996 - 2000

**Lecturer**, Clinical Therapeutics in Advanced Nursing Practice (NUSC5213), Cardiology Section. University of Arkansas College of Nursing 1996 - 2002

**Lecturer and Course Coordinator**, Advanced Cardiac Life Support (PhPr5882), an elective for Pharm.D. candidates in their third professional year, University of Arkansas College of Pharmacy 1996 - 1997

**Instructor**, Advanced Cardiac Life Support, University Hospital of Arkansas 1995 - 2002

**Preceptor**, Pharmacy Practice Residency Program, John L. McClellan VA Medical Center, a one month experience in Cardiovascular Therapeutics, 1995 - 2002

**Preceptor**, Pharmacy Practice Residency Program, University Hospital of Arkansas, a one month experience in Cardiovascular Therapeutics, 1995 - 2002

**Instructor**, Therapeutics Recitation I and II, case based instruction for Pharm.D. candidates in their third professional year, University of Arkansas College of Pharmacy 1995 - 1996

**Preceptor**, Adult Internal Medicine and Cardiology Clerkship for Pharm.D. candidates in their fourth professional year, University of Arkansas College of Pharmacy 1994 - 2002

**Lecturer**, Therapeutics I (Pharmacy Practice 5645), Cardiology Section, University of Arkansas College of Pharmacy 1994 - 2002

**Lecturer**, Clinical Pharmacology in Advanced Nursing Practice (NUSC 5213), Cardiology Section. University of Arkansas College of Nursing 1994-2002

**Preceptor**, Hospital Pharmacy Experiential Rotation for Pharm.D. candidates in their fourth professional year, Baptist Memorial Medical Center, North Little Rock Arkansas 1988 - 1993

## PUBLICATIONS

---

Wahawisan J, Tovar JM, **Granberry MC**. Statin Therapy: When to think twice. *J Fam Pract*. 2013; 62(12): 726-732.

Klepser ME, Matzke GR, Vivian Eva, **Granberry MC**, Majerus T, Wiggins B, Hill-Zabala C, Weimert N, Raebel MA. Ethical Issues Related to Clinical, Translational, and Health System Research. *Pharmacotherapy* 2008; 28(10):229e-243e

**Granberry MC**, Linn WD, Chilton R. Arrhythmias. In: Linn WD, O'Rourke RA, Posey LM, Wofford MR, O'Keefe ME, eds. *Pharmacotherapy in Primary Care*. New York, NY, McGraw-Hill; 2008.

Canales-Gonzales P, Kranz PL, **Granberry MC**, Tanguma J. An assessment of stress experienced by students in a prepharmacy curriculum. *Journal of Instructional Psychology*. 2008 [http://findarticles.com/p/articles/mi\\_m0FCG/is\\_1\\_35/ai\\_n25356479/](http://findarticles.com/p/articles/mi_m0FCG/is_1_35/ai_n25356479/)

**Granberry MC**, Hawkins JB, Franks AM. Thiazolidinedione-induced edema in patients with heart failure. [*Letter*] *Am J Health-Syst Pharm*. 2007;64:2427.

**Granberry MC**, Hawkins JB, Franks AM. Thiazolidinediones in Patients with Type 2 Diabetes Mellitus and Heart Failure. *Am J Health-Syst Pharm*. 2007;64:931-6.

**Granberry MC**, Fonseca VA. Cardiovascular Risk Factors Associated with Insulin Resistance: Effects of Oral Antidiabetic Agents. *Am J Cardiovasc Drugs*. 2005;5(3):201-9

Deyhim F, **Granberry MC**. (2004). Nutrition-related health issues—Cardiovascular disease. In R. Sue Day (Ed.), *Nourishing the future: The case for community-based nutrition research in the Lower Rio Grande Valley*. Houston: The University of Texas School of Public Health.

**Granberry MC**, Smith ES III, Troillett R, Eidt JF. Forearm Endothelial Response in Users of Smokeless Tobacco as Compared to Cigarette Smokers and Non-Tobacco Users. *Pharmacotherapy* 2003; 23(8): 974-978

**Granberry MC**, Stiegler KA. Documentation and Analysis of Increased Grade Point Averages at a College of Pharmacy over 20 years. *Am J Pharm Educ*; 2003 67 (3): 1-5.

**American Society of Health-System Pharmacists**. ASHP therapeutic statement on the use of statins in the prevention of atherosclerotic vascular disease. *Am J Health-Syst Pharm* 2003; 60: 593-598

Melchert RB, Liu H, **Granberry MC**, Kennedy RH. Lovastatin Inhibits Phenylephrine-Induced ERK Activation and Growth of Cardiac Myocytes. *Cardiovascular Toxicology* 2001; 1:237-252.

Johnson JT, **Granberry MC**, Thomas AR. Anticoagulation Management in Mechanical Heart Valve Patients Who Undergo Dental Procedures. *J Ark Med Soc* 2000; 97 (4):128-131.

**Granberry MC**, Smith ES, Talley JD. Raising HDL-C to Prevent Atherosclerotic Events. *J Ark Med Soc* 2000; 96 (10):378-9.

**Granberry MC**, Gardner SF, Smith ES. Reaching the Goal in the Treatment of Hypertension: Implications of the HOT Study. *Resident and Staff Physician* 1999; 45:44-48.

**Granberry MC**, Baliga BS, Fonseca VA. Clinical Pathophysiology of Painful Diabetic Neuropathy: The Role of Treatment with Gabapentin. *Practical Diabetology*. 1999; 18: 6-10.

**Granberry MC**, Fonseca VA. The Insulin Resistance Syndrome: Options for Treatment. *SMJ* 1999;92:2-14.

**Granberry MC**, Schneider EF, Fonseca VA. The Role of Troglitazone in Treating the Insulin Resistance Syndrome. *Pharmacotherapy* 1998; 18(5):973-987.

**Granberry MC**. Ibutilide: A New Class III antiarrhythmic agent. *Am J Health-Syst Pharm* 1998;55:255-260.

Gardner SF, Marx MA, White LM, **Granberry MC**, Fonseca V. Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. *Ann Pharmacother* 1997;31:677-682.

**Granberry MC**, Gardner SF, Carter IR, Schneider EF. A randomized, crossover trial comparing Adalat CC<sup>®</sup> to Procardia XL<sup>®</sup> during 24-hour blood pressure monitoring. *Pharmacotherapy* 1996;(5):932-936.

**Granberry MC**. Ibutilide Drug Monograph. Invited review published by University Hospital Consortium Services Corporation. May 1996.

Gardner SF, Schneider EF, **Granberry MC**, Carter IR. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. *Pharmacotherapy* 1996;16(3):419-423.

**Granberry MC**, Gardner SF. In the absence of terfenadine, can erythromycin cause QT prolongation that may result in torsade de pointes? *Ann Pharmacother* 1996;30:77-78.

**Granberry MC**, White LM, Gardner SF. Exacerbation of congestive heart failure after administration of polyethylene glycol-electrolyte lavage solution. *Ann Pharmacother* 1995;29:1232-5.

## PEER REVIEWED ABSTRACTS

---

DeLeon MA, Farrell NC, Coleman CA, **Granberry MC**. Preadmission Writing Samples as a Predictor of Academic Success of First-year Pharmacy Students. [abstract]. *Am J Pharm Edu*; 2011; 75(5) Article 105

**Granberry MC**, Maize DF and Coleman C. Knowledge and Perceptions of Accreditation from Applicants to a New School of Pharmacy. [abstract]. *Am J Pharm Edu* 2006;70(3) Article 65

**Granberry MC**, Canales PL, Jennifer Myhra. Analysis of Clinical Competency Test Performance by Faculty Status and by Geographic Region. [abstract]. *Am J Pharm Educ* 2005; 69(3) Article 60

Bellanger RA, **Granberry MC**, Mathes A. Continuing Professional Development (CPD) Survey – Responses from Texas Pharmacists. Proceedings of American Pharmacists Association annual meeting in San Francisco, March 2006

**Granberry MC**, Tijerina SL, Balli J, Evans MD. B-type natriuretic peptide levels are not increased in heart failure patients receiving thiazolidinediones. [abstract]. *Pharmacotherapy* 2005; 25:464

**Granberry MC**, Johnson JT, Myatt S, McAfferty R, Sabbe J, Warmack S, Smith ES. Comparison of evidence-based medicine knowledge between physician faculty, physician residents, and pharmaceutical industry representatives. [abstract]. *Pharmacotherapy* 2003; 23: 396

Stiegler KA, Franks AM, **Granberry MC**, Hawkins JB, Smith ES. Outcomes of antiarrhythmic drug therapy in patients with systolic heart failure and atrial fibrillation. *Pharmacotherapy* 2003; 23: 391

**Granberry MC**, Garza RF, McIntyre WJ. Assessment of student professionalism during acute care clerkships at colleges of pharmacy [abstract]. Published in Meeting Abstracts: 104th Annual Meeting, July 20-23, 2003, Minneapolis, Minnesota. *Am J Pharm Educ.* 2003;4 Article 100

**Granberry MC**. Documentation and Analysis of Increased Grade Point Averages at a College of Pharmacy Over 20 Years. [abstract]. Published in Meeting Abstracts: 104th Annual Meeting, July 20-23, 2003, Minneapolis, Minnesota. *Am J Pharm Educ.* 2003;4 Article 100

Franks AM, **Granberry MC**, Glover F, Hawkins JB, Smith ES. Non-steroidal anti-inflammatory drugs do not increase major events in heart failure patients. [Abstract] Published in Meeting Abstracts: Asia Pacific Scientific Forum: The 43rd Annual Conference on Cardiovascular Disease and Epidemiology; April 2002, Honolulu, HI.

**Granberry MC**, Hawkins JB, Franks AM, Smith ES. Delayed use of  $\beta$ -blockers therapy in heart failure patients. [abstract]. *Pharmacotherapy* 2002; 22:405

**Granberry MC**, Troillett R, Eidt J, Smith ES. Forearm endothelial response in users of smokeless tobacco as compared to cigarette smokers and non-tobacco users. [abstract]. *Pharmacotherapy* 2002; 22:405.

Hawkins JB, **Granberry MC**, Franks AH, Smith ES. Evaluation of metoprolol therapy in a heart failure population. [abstract]. *Am J Health-Syst Pharm* 2001; 58:1982.

**Granberry MC**, Hawkins JB, Franks AH, Smith ES.  $\beta$ -Blocker use in a population of veterans with heart failure. [abstract]. *Pharmacotherapy* 2001; 21:1260.

R. B. Melchert, H. Liu, **M. C. Granberry**, R. H. Kennedy. Lovastatin inhibits phenylephrine-induced ERK activation and growth of cardiac myocytes. [abstract]. *The Toxicologist.* 60:12-13, 2001.

McCormack JR, Wolfe JJ, Grady AL, **Granberry MC**, Allen B. 1998 Study Finds 36% of Adult Medicine Hospitalizations Could Have Been Prevented by Level-2 Pharmacist Interventions. [abstract]. *Am J Pharm Educ* 1999;63:S81



**Granberry MC**, Johnson, JT, Stafford A, Carthan N. Implementation and Evaluation of Patient Case-Based Discussion of Optimal Therapy Derived From Landmark Studies and Consensus Statements. [abstract]. *Am J Pharm Educ* 1998;62:110S

Coulter L, Grady AR, **Granberry MC**, Geurian K, Johnson JT, Marsh C, McCafferty R, Myatt SM, Schneider EF. Case-Based lecture versus standard lecture style. [abstract]. *Am J Pharm Educ* 1998; 61:80S

Johnson JT, **Granberry MC**. Reimbursement of pharmacist's cognitive services for anticoagulation and hyperlipidemia management. [abstract]. *Pharmacotherapy*. 1996;16(3):517

Gardner SF, Marx MA, **Granberry MC**, Skelton DR, Fonseca VA. Low-dose niacin and pravastatin in diabetic patients with dyslipidemias. [abstract]. *Pharmacotherapy* 1995;15:372.

Schneider EF, Gardner SF, **Granberry MC**, Carter IR. Is it safer and more effective to add low-dose niacin to low-dose HMG-CoA reductase inhibitor than to increase the dose of the HMG-CoA reductase inhibitor in patients failing to respond to initial therapy? [abstract]. *Pharmacotherapy* 1995;15:403

**Granberry MC**, Gardner SF, Schneider EF, Carter IR. Comparison of Adalat CC® versus Procardia XL® with twenty-four hour ambulatory blood pressure monitoring. [abstract]. *Pharmacotherapy* 1995;15:394

## RESEARCH/CONTRACTS

---

The Thiazolidinediones and Brain Natriuretic Peptide (Principal Investigator) Funded by Office of Biomedical Research Resources, The University of Texas – Pan American \$6,430.00 (2003)

Documentation and Analysis of Potential Grade Inflation at a College of Pharmacy Over 20 Years (Principal Investigator) Unfunded (2002)

Evaluation of Clinician's Knowledge of Statistical Methods and Clinical Significance. (Principal Investigator) Unfunded (2001)

Retrospective Evaluation of the Medical Management of Patients with Left Ventricular Systolic Dysfunction. (Principal Investigator) Funded by Smith-Kline Beecham \$3000.00

Forearm Endothelial Response in Users of Smokeless Tobacco as Compared to Cigarette Smokers: A Pilot Study. (Principal Investigator) Unfunded (1999)

HMG-CoA Reductase Inhibition and Repression of Cardiac Hypertrophy. Funded by Parke-Davis, and Co. (Co-Investigator) \$25,625.00 (1999)

A Multicenter, Six Week, Randomized, Open-Label, Parallel Arm Study Comparing the Efficacy of Once Daily Atorvastatin to Simvastatin in Hypercholesterolemic Patients, Contract with Parke-Davis, Medical Research, (Co-Investigator) \$69,000.00 (1998)

Forearm Endothelial Response to Atorvastatin and Troglitazone in Non-insulin Dependent Diabetic Patients (Principal Investigator) Funded by a grant from Parke-Davis and Co. \$73,500.00 (1997)

Can Pharmacist Intervention and Education Prevent Hospital Re-Admission for Congestive Heart Failure? (Co-Investigator) Funded by National Association for Retail Druggists \$10,000.00 (1996)

A Comparison of the Fibrinogen, Homocysteine, and Plasma Lipid Modification by Metformin and Pravastatin When Used Separately or in Combination in Non-insulin Dependent Diabetic Patients. (Principal Investigator) Funded by Bristol-Myers Squibb \$9,600.00 (1996)

Case-Based Lecture Versus Standard Lecture. (Co-Investigator) 1996

Low-dose lovastatin plus niacin versus higher dose lovastatin. (Co-Investigator) Funded by Bristol-Myers Squibb Family Medicine Research Award, ACCP Research Institute. \$10,000.00 (1994)

Once daily Procardia XL versus once daily Adalat CC for twenty-four blood pressure control. (Principal Investigator) (1994)

Effect of niacin on lipids and glucose control when added to pravastatin in diabetic patients. (Co-Investigator) Funded by R. Clifton Brooks Medical Research Fellowship Program of the Sons of the Confederate Veterans. (1994)

#### **RESEARCH GRANTS UNFUNDED**

---

The Effect of Exercise on Inflammatory Markers in Obese Children (Principal Investigator of subgrant) RIMI \$231,087.00 (2004)

Comparison of Health Interventions Between Hispanic and Non-Hispanic Diabetics. Submitted to the Centers for Medicare and Medicaid Services. (Co-Investigator) \$223,523.00 (2003)

HMG-CoA Reductase Inhibitors and Cardiac Hypertrophy. Submitted to Atorvastatin Research Awards Program (Co-Investigator) \$49,814.00 (1999)

Effect of Atorvastatin on Cyclosporine Pharmacokinetics in Heart Transplant Patients. Submitted to Parke-Davis, and Co. (Co-Investigator) \$35,000.00 (1999)

Differential Effects of Lipophilic and Hydrophilic HMG-CoA Reductase Inhibitors on Cardiac Myocytes: An Advantage for Hydrophilic Agents? (Co-Principal Investigator) Grant proposal submitted to Bristol-Myers Squibb, Inc. \$10,000.00 (1998)

HMG-CoA Reductase Inhibitors and Cardiac Hypertrophy. (Co-Investigator) Submitted to the Pharmaceutical Research and Manufacturers of American Foundation. \$25,000.00 (1998)

Lipid Lowering Therapy for Secondary Prevention after Acute Myocardial Infarction: Prescribed Use and Outcomes. (Principal Investigator) \$2,500.00 (1997)

Forearm Endothelial Response to Sildenafil in Non-insulin Dependent Diabetic Patients. (Principal Investigator) Grant proposal submitted to Pfizer Inc. \$16,762.50 (1998)

The Effect of Cerivastatin on Hemostatic Risk Factors Associated with Cardiovascular Disease. (Principal Investigator) Grant proposal submitted to SmithKline Beecham. \$20,862.50 (1998)

## POSTER PRESENTATIONS

---

Gilliland K, **Granberry MC**. Evidence based teaching in United States doctor of pharmacy pharmacotherapy education: a preliminary study. American Society of Health-System Pharmacists Midyear Clinical Meeting. Orlando, FL December 9, 2013

Patel P, Granberry MC. Retrospective Evaluation of the Safety of Drug Therapy for the Initial Management of Hypertensive Urgencies. ASHP Midyear Clinical Meeting, Las Vegas, NV December 2012

DeLeon MA, Farrell NC, Coleman CA, Granberry MC. Preadmission Writing Samples as a Predictor of Academic Success of First-year Pharmacy Students. Am J Pharm Edu; 2011; 75(5) Article 105

**Granberry MC**, Witte AP, Barnes JN. Author's Contribution to Posters Presented at a National Pharmacy Meeting Did Not Consistently Adhere to the International Committee of Medical Journal Editors (IMJE) Guidelines. Poster presentation at the ASHP Midyear Meeting, December 2007

**Granberry MC**, Maize DF and Coleman C. Knowledge and Perceptions of Accreditation from Applicants to a New School of Pharmacy. Poster presentation at American Association of Colleges of Pharmacy Annual Meeting, San Diego, CA, July 9, 2006

Bellanger RA, **Granberry MC**, Mathes A. Continuing Professional Development (CPD) Survey – Responses from Texas Pharmacists. Poster presentation at the American Pharmacists Association annual meeting in San Francisco, March 2006

**Granberry MC**, Canales PL, Myhra J. Analysis of Clinical Competency Test Performance by Faculty Status and By Geographic Region. Poster presentation at American Association of Colleges of Pharmacy Annual Meeting, Cincinnati OH, July 10, 2005

**Granberry MC**, Evans ME, Tijerina S. B-type natriuretic peptide levels not increased in heart failure patients receiving thiazolidinediones. Poster presentation at the American College of Clinical Pharmacy Spring Practice and Research Forum, Myrtle Beach, SC April 11, 2005

**Granberry MC**, Garza R, McIntyre WJ. Assessment of student professionalism during acute care clerkships at colleges of pharmacy. Poster presentation at the American Association of Colleges of Pharmacy Annual Meeting, Minneapolis MN, July 22, 2003

**Granberry MC**, Stiegler KA. Documentation and analysis of increased grade point averages at a college of pharmacy over 20 years. Poster presentation at the American Association of Colleges of Pharmacy Annual Meeting, Minneapolis MN, July 22, 2003

**Granberry MC**, Johnson JT, Myatt S, McAfferty R, Sabbe J, Warmack S, Smith ES. Comparison of evidence-based medicine knowledge between physician faculty, physician residents, and pharmaceutical industry representatives. Poster presentation at the American College of Clinical Pharmacy Spring Practice and Research Forum, Palm Springs, CA April 29, 2003

Steigler KA, Franks AM, **Granberry MC**, Hawkins JB, Smith ES. Outcomes of antiarrhythmic drug therapy in patients with systolic heart failure and atrial fibrillation. Poster presentation at the American College of Clinical Pharmacy Spring Practice and Research Forum, Palm Springs, CA April 29, 2003

**Granberry MC**, Hawkins JB, Franks AM, Smith ES. Delayed use of  $\beta$ -blockers therapy in heart failure patients. Poster presentation at the American College of Clinical Pharmacy Spring Practice and Research Forum, Savannah, GA, April 9, 2002

**Granberry MC**, Troillett R, Eidt J, Smith ES. Forearm endothelial response in users of smokeless tobacco as compared to cigarette smokers and non-tobacco users. Poster presentation at the American College of Clinical Pharmacy Spring Practice and Research Forum, Savannah, GA, April 9, 2002

Hawkins JB, **Granberry MC**, Franks AM, Washam S, Smith ES. Evaluation of metoprolol therapy in a heart failure population. Poster presentation at the 36<sup>th</sup> Annual American Society of Health-System Pharmacists Midyear Clinical Meeting, December 2-6, 2001. New Orleans, LA

**Granberry MC**, Hawkins JB, Franks AH, Smith ES.  $\beta$ -Blocker use in a population of veterans with heart failure. Poster presentation at the American College of Clinical Pharmacy Annual Meeting, Tampa, FL October 28, 2001

**Granberry MC**, Hawkins J, Franks AM, Learned R, Smith ES. Use of beta-blockade in a heart failure population. Poster presentation at the 35<sup>th</sup> Annual Arkansas Association of Health-System Pharmacists Fall Seminar. October 4, 2001. Little Rock, Arkansas

**Granberry MC**, Johnson JT. Implementation and Evaluation of Patient Case-Based Discussion of Optimal Therapy Derived From Landmark Studies and Consensus Statements. Poster presentation at the American Association of Colleges of Pharmacy Annual Meeting, Aspen, Colorado. July 21, 1998.

**Granberry MC**, Gardner SF, Schneider EF, Carter IR. Comparison of Adalat CC versus Procardia XL with twenty-four hour ambulatory blood pressure monitoring. Poster presentation at American College of Clinical Pharmacy Annual Meeting, Washington, DC. August 5, 1995.

## INVITED LECTURES AND PRESENTATIONS

"Basics of Clinical Trial Evaluation" Gulf Coast Pharmacy Continuing Education Program Corpus Christi, TX. February 25, 2017

"Diuretic Therapy for Acute Decompensated Heart Failure" Texas Society of Health-System Pharmacists Annual Meeting, San Antonio, TX April 14, 2015

"Antiplatelet Therapy for Ischemic Stroke" HCA Residency Program, Corpus Christi, TX. April 14, 2015

"Diuretic Resistance" CHRISTUS Spohn Family Medicine Residency Program, Corpus Christi, TX. May 15, 2014.

"Lipid-Therapy for Special Populations". Texas Society of Health-System Pharmacists Annual Meeting, Houston, TX April 12, 2014

"Antiplatelet Therapy: Current Use in the Acute Coronary Syndromes". Gulf Coast Pharmacy Continuing Education Program. Corpus Christi, Texas September 29, 2012

"Use of Aldosterone Antagonists and Ivabradine in Treating Heart Failure". Clinical Pharmacy Week. Vienna, Austria September 10, 2012

“Stroke: Optimal Pharmacotherapy for Primary and Secondary Prevention”. Clinical Pharmacy Week. Vienna, Austria September 12, 2012

“Antiplatelet Therapy: Current Use in the Acute Coronary Syndromes”. Clinical Pharmacy Week. Vienna, Austria September 10, 2012

“Hypertension: Review of the Guidelines and Update”. Clinical Pharmacy Week. Vienna, Austria September 10, 2012

“Setting Up A Rotation”. Preceptor training for the Rangel College of Pharmacy, Corpus Christi, Texas June 2012.

“Evidence-Based Drug Therapy”. Continuing education presentation for the Central Texas Society of Health-System Pharmacists. San Antonio, Texas, September 8, 2008

“Gambling on Drug Therapy: How to Improve Your Odds When Interpreting the Medical Literature” Continuing education presentation at the UIW School of Pharmacy Preceptor Conference, San Antonio TX, October 26-27, 2007

“The Use of Insulin Sensitizers in Patients with Heart Failure: The Risks Outweigh the Benefit” Platform presentation at the 40<sup>th</sup> Annual Midyear Clinical Meeting of the American Society of Health-System Pharmacists. Las Vegas, Nevada, December 7, 2005

“Gambling on Drug Therapy: How to Improve Your Odds When Interpreting the Medical Literature” Platform Presentation at the Fall UT-Austin College of Pharmacy CE Seminar, Edinburg TX, October 19, 2003

“Frequently Asked Questions About Anti-platelet Therapy” UAMS College of Medicine Continuing Medical Education Program. Hot Springs, Arkansas March 23, 2002

“Forearm Endothelial Response in Users of Smokeless Tobacco as Compared to Cigarette Smokers and Non-Tobacco Users” UAMS College of Pharmacy Pharmaceutical Sciences Seminar. Little Rock, Arkansas October 5, 2001

“New Developments in Lipid Management” Presentation at the Fall Symposium of the Mid-South College of Clinical Pharmacy. Memphis, Tennessee September 9, 2000

“A Clinical Perspective on Insulin Resistance: Pathogenesis, Identification, and Treatment” Continuing Education Presentation to pharmacists. Jonesboro, Arkansas, June 23, 1999; Alexandria, LA, July 8, 1999; Oklahoma City, OK July 27, 1999; Green Bay, WI, October 7, 1999; Shreveport, LA, December 9, 1999

“Reimbursement of pharmacist’s cognitive services for anticoagulation and hyperlipidemia management” Johnson JT and Granberry MC. Poster presentation at the American College of Clinical Pharmacy Annual Meeting, Nashville, TN. August 6, 1996.

“New Models for Nontraditional Experiential Education” Platform presentation at the American Association of Colleges of Pharmacy Annual Meeting, Reno, NV. July 13, 1996.

## **PROFESSIONAL APPOINTMENTS AND SERVICE**

Chair, Residency Review Committee. University of Arkansas for Medical Sciences College of Pharmacy, Department of Pharmacy Practice 2017-present

Chair, Residency Program Directors Committee. University of Arkansas for Medical Sciences College of Pharmacy, Department of Pharmacy Practice 2017-present

Member, Curriculum 2025 Committee. University of Arkansas for Medical Sciences College of Pharmacy 2017-2018

Member, Accreditation Council for Pharmacy Education (ACPE) Self-Study Committee, Texas A&M Health Science Center Rangel College of Pharmacy, 2014-2015

Member, Strategic Plan Task Force: Education Sub-Committee, Texas A&M Health Science Center Rangel College of Pharmacy, 2013

Chair, Search Committee: Program Manager Experiential Education, Texas A&M Health Science Center Rangel College of Pharmacy, 2013

Chair, Search Committee: Pharmacy Practice Faculty Search, Texas A&M Health Science Center Rangel College of Pharmacy, 2012 to present

Clinical Specialist, Cardiovascular Intensive Care Unit, CHRISTUS Spohn Memorial Hospital, Corpus Christi, TX, 2012 to 2017

Co-Chair, Search Committee: Director of Introductory Practice Experiences, Texas A&M Health Science Center Rangel College of Pharmacy, 2011 to 2012

Member, QEP Committee. Texas A&M Health Science Center Rangel College of Pharmacy, 2011 to 2016

Chair, Departmental Appointment, Promotion and Tenure Committee. Texas A&M Health Science Center Rangel College of Pharmacy, 2011 - 2013

Chair, Curricular Affairs Committee. Texas A&M Health Science Center Rangel College of Pharmacy, 2011 to 2016

Clinical Specialist, Cardiovascular Intensive Care Unit, University Hospital, San Antonio, Texas 2009 to 2010

Member, University of the Incarnate Word, Rank and Tenure Committee, 2009 - 2010

Chair, Accreditation Council for Pharmacy Education Writing Committee, School of Pharmacy, University of the Incarnate Word, 2008 – 2010

Clinical Pharmacy Specialist, South Texas Veterans Affairs Medical Center, San Antonio, Texas 2006 – 2008

Member, Public and Professional Affairs Committee, American College of Clinical Pharmacy, 2007-2008

Member, Editorial Board, Texas Society of Health System Pharmacists, 2006 to 2010

Member, Faculty Affairs Committee, University of the Incarnate Word, San Antonio, Texas 2006 - 2008

Member, Publications Committee, American College of Clinical Pharmacy, 2005-2006

Chair, Institutional Review Board, University of the Incarnate Word, 2005 – 2007

Member, Admission and Academic Standards Committee, University of the Incarnate Word School of Pharmacy, 2005 – 2009

Member, Curriculum Committee, University of the Incarnate Word School of Pharmacy, 2005 – 2008

Member, Core Curriculum Review Committee, University of Texas – Pan American, 2004

Member, Strategic Planning Committee, College of Health Sciences and Human Services, The University of Texas – Pan American, 2003-2004

Member, Research Committee, College of Health Sciences and Human Services, The University of Texas – Pan American, 2003-2004

Chair, Assistant Dean Search Committee, University of Texas – Pan American, 2003-2004

Chair, Institutional Review Board, University of Texas – Pan American, 2003-2004

Member, Faculty Search Committee, Cooperative Pharmacy Program, The University of Texas – Pan American 2003–2004

Member, Pharmacy Scholars Program Admissions Committee, The University of Texas – Pan American 2002–2004

Member, Faculty Search Committee, Physician Assistant Studies Program, University of Texas – Pan American 2002–2004

Member, American Council of Pharmaceutical Education Accreditation Committee, College of Pharmacy, University of Arkansas for Medical Sciences, 2001

Member, Promotion and Tenure Committee, College of Pharmacy, University of Arkansas for Medical Sciences, 2001-2002

Member, Scholastic Standing Committee, College of Pharmacy, University of Arkansas for Medical Sciences, 2001-2002

Member, Curriculum Committee, College of Pharmacy, University of Arkansas for Medical Sciences, 2000-2002

Member, Editorial Advisory Board, Journal of the American Pharmaceutical Association, Special Issue Series: Avandia, 1999

Member, Editorial Advisory Board, Journal of the American Pharmaceutical Association, Special Issue Series: Insulin Resistance, 1999

Member, Disease State Management Examination Review Committee, National Association of Boards of Pharmacy. 1999-present

Member, Cardiology Item Writing Panel, BPS Specialty Council on Pharmacotherapy. 1998 - present

Member and Lipid Section Coordinator, Disease State Management Committee, College of Pharmacy, University of Arkansas for Medical Sciences, 1998-2002

Member, Item Writing Committee for Disease State Management, National Association of Boards of Pharmacy, 1998

Member, Undergraduate Admissions Committee, College of Pharmacy, University of Arkansas for Medical Sciences, 1997 - 1999

Consultant, Angioplasty Clinical Pathway Development Committee, University Hospital of Arkansas, University of Arkansas for Medical Sciences, Little Rock Arkansas, 1996

Consultant, Pharmaceutical Care Committee, University Hospital, University of Arkansas for Medical Sciences, Little Rock Arkansas, 1996

Coordinator and Member, Lipid Management Clinic, University Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas, 1995-2002

Member, Anticoagulation Clinic, University Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas, 1995-2002

Member, Drug Utilization Review (DUE) Subcommittee, University Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas, 1995-2002

Consultant, Patient Focused Care Committee, Baptist Medical System, Little Rock Arkansas, 1995

Member, Clinical Pharmacokinetic Monitoring Service, University Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas, 1994-1999

Reviewer: The Annals of Pharmacotherapy, 1994 - 1995